Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
<p>Abstract</p> <p>A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiatio...
Main Author: | Copeman Michael |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-11-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Online Access: | http://www.jeccr.com/content/27/1/59 |
Similar Items
-
Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
by: Yunjian HUANG, et al.
Published: (2009-12-01) -
The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01) -
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
by: William Pao, et al.
Published: (2005-01-01) -
Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report
by: Xiaoyan LI, et al.
Published: (2016-01-01) -
A Case Report of Erlotinib as First-line Therapy in Extensive Metastatic Patient with Advanced Non-small Cell Lung Cancer
by: Xiaoqing LIU, et al.
Published: (2009-12-01)